Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eun Young | - |
dc.contributor.author | Kim, An Keun | - |
dc.date.available | 2021-02-22T12:47:19Z | - |
dc.date.issued | 2012-01-31 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.issn | 2005-4483 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/11995 | - |
dc.description.abstract | TNF-related apoptosis-inducing ligand (TRAIL) is a promising agent for management of cancer because of its selective cytotoxicity to cancer cells. However, some cancer cells have resistance to TRAIL. Accordingly, novel treatment strategies are required to overcome TRAIL resistance. Here, we examined the synergistic apoptotic effect of apigenin in combination with TRAIL in Huh-7 cells. We found that combined treatment of TRAIL and apigenin markedly inhibited Huh-7 cell growth compared to either agent alone by inducing apoptosis. Combined treatment with apigenin and TRAIL induced chromatin condensation and the cleavage of poly (ADP-ribose) polymerase (PARP). In addition, enhanced apoptosis by TRAIL/apigenin combination was quantified by annexin V/PI flow cytometry analysis. Western blot analysis suggested that apigenin sensitizes cells to TRAIL-induced apoptosis by activating both intrinsic and extrinsic apoptotic pathway-related caspases. The augmented apoptotic effect by TRAIL/apigenin combination was accompanied by triggering mitochondria-dependent signaling pathway, as indicated by Bax/Bcl-2 ratio up-regulation. Our results demonstrate that combination of TRAIL and apigenin facilitates apoptosis in Huh-7 cells. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN SOC APPLIED PHARMACOLOGY | - |
dc.title | Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4062/biomolther.2012.20.1.062 | - |
dc.identifier.scopusid | 2-s2.0-84857187752 | - |
dc.identifier.wosid | 000300469100008 | - |
dc.identifier.bibliographicCitation | BIOMOLECULES & THERAPEUTICS, v.20, no.1, pp 62 - 67 | - |
dc.citation.title | BIOMOLECULES & THERAPEUTICS | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 62 | - |
dc.citation.endPage | 67 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001630283 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | LIGAND (TRAIL)-INDUCED APOPTOSIS | - |
dc.subject.keywordPlus | BREAST-CANCER CELLS | - |
dc.subject.keywordPlus | PROTEASOMAL DEGRADATION | - |
dc.subject.keywordPlus | MEDIATED APOPTOSIS | - |
dc.subject.keywordPlus | HUMAN HEPATOCYTES | - |
dc.subject.keywordPlus | PROSTATE-CANCER | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordAuthor | TRAIL | - |
dc.subject.keywordAuthor | Huh-7 | - |
dc.subject.keywordAuthor | Combination | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Caspase family | - |
dc.subject.keywordAuthor | Bcl-2 family | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.